Skyrizi (risankizumab), initially approved to treat Crohn s disease, psoriatic arthritis and psoriasis, has achieved clinical remission in 40% of patients with ulcerative colitis.
Data illustrates AbbVie s commitment to providing research and innovative solutions that support patients with high disease burden and unmet needOral presentations address treatment of moderate to severe Crohn s disease, including